Nightingale’s internationally recognised blood analysis technology utilises NMR (nuclear magnetic resonance) and proprietary software to provide comprehensive health data that links a person’s lifestyle to their disease risk.
It all starts with a single blood sample that goes through a fully automated NMR analysis process under strict quality control and provides a comprehensive spectrum analysis of numerous biomarkers from the sample. Our in-house software then identifies the metabolites and quantifies this data to provide detailed insights about a person’s health.
Würtz et al. American Journal of Epidemiology 2017;186(9):1084–96
Nightingale is committed to achieving high quality in all its services. Quality and compliance with all applicable regulatory and customer requirements underline all our operations.
Nightingale's laboratory is an accredited testing laboratory. The Nightingale Health Plc laboratory T333 is accredited by the FINAS Finnish Accreditation Service, accreditation criteria SFS-EN ISO/IEC 17025. Scope of accreditation for clinical services and sites are available at www.finas.fi
Nightingale Health operates under a certified quality management system in accordance with EN ISO 13485:2016 (certified by DEKRA Certification B.V.).
Nightingale measures blood samples with a CE-marked IVD device.
Nightingale Health participates in UK NEQAS and WEQAS programs to monitor its measurement quality between Nightingale and other laboratories.
Procedures for clinical laboratory tests are based on standard for medical laboratories (EN ISO 15189) and blood samples are measured with a CE-marked IVD device. Clinical laboratory tests are calibrated to standard materials provided by National Institute of Standards and Technology (NIST). Method validation is done according to CLIA’s US FDA recognised consensus standards.
Nightingale tech was developed as a result of research need—an affordable method that could harvest large amounts of data from small blood samples—to have a deeper understanding of disease etiology. Using a combination of NMR (nuclear magnetic resonance) and proprietary quantification software, we’ve developed a much faster and cost-effective technology that could analyse a multitude of data points from a single blood sample.
Since then this path-breaking technology has been used in over 300 scientific studies by researchers worldwide to make novel findings and create new knowledge that helps predict and prevent chronic diseases. For instance, how amino acids reflect the future risk for heart disease and diabetes and uncovered the role of chronic inflammation as an indicator of increased risk across many seemingly different disease types. This new knowledge has paved the way for My Nightingale, our first step towards abolishing chronic diseases by predicting, preventing and averting them.
With this technology, we not only aim to empower individuals but build a health creation system where decision-makers have the tools make difference at a community level. With anonymised aggregated data, those responsible for the health and wellbeing of companies, nations and global organisations, will be able to predict the future health of their communities and make informed choices that will build healthier societies.
Whether you have a question or you would like to ask for an offer, let us know and we'll get back to you very soon.